All News

There may be an association between the regular use of statins and reduced mortality in patients with alcoholic cirrhosis-a chronic liver disease often caused by alcohol consumption.

As obesity rates increase, health systems will have to take charge of finding places to discharge the largest patients to avoid penalties from Medicare, authors of a new study find.

A new extended release oral suspension for the treatment of attention-deficit/hyperactivity disorder in patients 6 or older was approved by the FDA and would provide an option for patients seeking a liquid treatment instead of a pill or capsule. Michael Feld, MD, a child, adolescent, and adult psychiatrist in the Chicago area specializing in the treatment of ADHD, explained what the benefits of Adzenys ER from Neos Therapeutics are for both patients and physicians.

A new case study of 12 advanced primary care practices found that none provided comprehensive cancer survivorship care, which the authors attributed to insufficient information systems and difficulties identifying survivors.

Advancements in the cancer immunotherapy pipeline are leading to the production of immune checkpoint inhibitors, and a recent report from Global Business Intelligence (GBI) Research titled “Cancer Immunotherapies-First-in-Class Pipeline Dominated by Immunomodulators and PD-1 Like Targets” took a look at the pipeline.

The FDA has announced the 9 companies that will participate in a pilot precertification program to speed the approval of digital health software.

Time is running out for Congress to reauthorize funding for the Children’s Health Insurance Program (CHIP) before it expires on September 30, leaving states and families to prepare for possible coverage reductions and higher premiums.

Adults with moderate-to-severe atopic dermatitis who were treated with Dupixent (dupilumab) from Sanofi and Regeneron along with topical corticosteroids experienced improvements in overall disease severity, according to results from phase 3 of the CAFÉ trial.

When Donald Trump was elected president in November 2016, repealing the Affordable Care Act (ACA) suddenly became an attainable goal for Republicans in Congress, though it ultimately did not come to fruition as they had hoped. Here, we look back at the legislative twists and turns of ACA repeal efforts in 2017.

Senate Majority Leader Mitch McConnell, R-Kentucky, announced that the Senate would not vote on the bill to repeal the Affordable Care Act (ACA) in light of a shortage of votes.

Among women treated at health centers receiving federal funding under Title X, the proportion receiving cervical cancer screening tests declined significantly from 2005 to 2015, according to new research.

The pilot program is the latest venture among stakeholders in diabetes care to look for ways to deploy patient data to improve outcomes and hold down costs.

At the National Comprehensive Cancer Network's Oncology Policy Summit, a physician administrator from the MD Anderson Cancer Center discussed weaving the patient focus into outcomes measurements.

Collins cited projections for large cuts to Medicaid in explaining her opposition to the proposal.

A new analysis finds that the mortality rate from chronic respiratory diseases has risen by almost 30% between 1980 and 2014 in the United States, and that data reflect significant differences in death rates across counties and regions.

While little seems certain about the current healthcare reform debate in Congress, the transition to value-based care is well underway. We are beginning to see that when providers are paid to deliver better care at lower costs, they can have a real impact on both.

A primary care physician finds there's little incentive to keep up with a patient-centered medical home, except that it's the right thing to do.

While the FDA’s approval of the immunotherapy tisagenlecleucel represents a landmark in the oncology field, the treatment is far from being a cure and should be viewed in context of its $475,000 price tag, a group of oncologists wrote in a commentary published in JAMA.

The FDA has rejected an abuse-deterrent opioid citing the need for further evidence. Rexista, an Oxycodone Hydrochloride Extended-Release tablet (Oxycodone ER), was developed by Intellipharmaceutics International Inc as an abuse- and alcohol-deterrent controlled-release oral formulation of oxycodone hydrochloride for pain relief.

Researchers at the London School of Economics and Political Science have developed a multiple criteria decision analysis model, The Advance Value Framework, that payers can utilize for evaluating new medicines that come to the market.

A new study finds that participating in the Supplemental Nutrition Assistance Program (SNAP) is associated with significantly lower healthcare expenditures, pointing to the role of social determinants like food insecurity as contributors to health spending.

The move to give entrepreneurs access to patient-approved continuous glucose monitoring data fits with the company's prediction that insulin pumps will become a thing of the past, and most of the heavy lifting of delivery will be done by a smartphone.

The increasing trend in long-term prescription opioid use in the United States calls for further research on the potential benefits and harm, according to a study.

There is a dimensional relationship that links white matter structure to neurodevelopmental symptoms, such as those associated with autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD). However, more research on the connection is necessary.

Neighborhood disadvantage may be an important determinant of the risks of major atherosclerotic cardiovascular disease (ASCVD)—related events, according to a new study.

Outcomes-based pricing arrangements for pharmaceuticals are increasingly popular. In this piece, we discuss the impact of the outcomes-based pricing arrangements proposed by Amgen on the pricing of PCSK9 inhibitor therapy, and we provide recommendations for payers on the design of outcomes-based contracts.

When immune-related adverse events arise from nivolumab, it may indicate that the therapy is having greater efficacy against non—small-cell lung cancer (NSCLC), as a new study demonstrates a link between these events and improved survival outcomes.